# DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

> **NCT01423812** · PHASE4 · COMPLETED · sponsor: **Ruth M. Rothstein CORE Center** · enrollment: 60 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Twice-daily combination Darunavir and ritonavir
- **DRUG:** Once-daily combination Darunavir and ritonavir

## Key facts

- **NCT ID:** NCT01423812
- **Lead sponsor:** Ruth M. Rothstein CORE Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-05
- **Final completion:** 2015-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423812, "DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01423812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*